About the AuthorMy name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
My ProfileI am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!
About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
June 2023 M T W T F S S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Legislative Tracking Tools
Category Archives: Safety and Clinical Trials
Is Congress the New FDA?
Given the dismal track record of the U.S. Senate in the 111th Congress in producing important legislation to improve the lives of Americans, it appears that some of that body's members are looking for new things to do. In the … Continue reading
Posted in FDA Image, Safety and Clinical Trials 3 Comments
The New FDA Drug Safety Initiative – Policy and Communications Implications
Yesterday the FDA announced yet another new initiative on drug safety. This is apparently in addition to the pre-existing Drug Safety Initiative. It is an action taken in response to the Institute of Medicine (IOM) report – The Future of … Continue reading
Posted in FDA Image, Risk Management, Safety and Clinical Trials Comments Off on The New FDA Drug Safety Initiative – Policy and Communications Implications
Tragedy in Britain – Magnifying the Risk in the Risk/Benefit Equation
By now you have probably heard the terrible story out out of the United Kingdom regarding six human volunteers in a Phase I study who became seriously ill almost immediately after taking a study medication. An analysis of the situation … Continue reading
Posted in Safety and Clinical Trials Comments Off on Tragedy in Britain – Magnifying the Risk in the Risk/Benefit Equation
Where Do You Stand on Phase IV Studies?
Last week, there were reports that the FDA came out with its annual report on how drug companies are faring with respect to keeping their post-marketing study commitments. The report card was not so hot. A whopping 65% of the … Continue reading
Posted in Safety and Clinical Trials Comments Off on Where Do You Stand on Phase IV Studies?
Considerations for a New Regulatory Environment
February 15, 2006 – This is a time for a lot of soul searching on the part of industry as well as the FDA. Events of the past two years are shaping an entirely new landscape in drug development and … Continue reading
Posted in Safety and Clinical Trials Comments Off on Considerations for a New Regulatory Environment